Significance of certain leukocyte indices in patients with type 2 diabetes who have had novel coronavirus infection
https://doi.org/10.21518/ms2025-375
Abstract
Сhronic low-intensity inflammation is the one of the mechanisms of development of diabetes mellitus type 2. In order to objectify this process, some leukocyte indices are used (the ratio of neutrophils to lymphocytes – NLR, the ratio of platelets to lymphocytes – PLR, the ratio of lymphocytes to monocytes – LMR, the ratio of monocytes to lymphocytes – MLR, as well as the index of systemic immune inflammation SII (calculated taking into account neutrophils, lymphocytes, platelets), taking into account the presence of both microvascular and macrovascular late complications in patients with diabetes mellitus. The new coronavirus infection significantly increases the inflammation process that’s why some leukocyte indices are to be prognostic markers of the disease outcomes. The article presents the latest data on the significance of inflammation markers in multimorbid patients with a new coronavirus infection. It is emphasized that data on the study of leukocyte indices in patients with diabetes mellitus who have had a new coronavirus infection are scarce, and information on the use of such a simple tool for studying inflammation as leukocyte indices in assessing post-COVID disorders in patients with diabetes mellitus is absent. Our data concluded that the learning information about inflammation in patients with type 2 diabetes and post-COVID syndrome using leukocyte indices is really promising.
About the Authors
S. A. Sukhanov
Privolzhsky Research Medical University
Россия
Россия
Sergey A. Sukhanov, Assistent of the Department of Therapy and General Medical Practice
10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950, Russia
Yu. A. Sorokina
Privolzhsky Research Medical University
Россия
Россия
Yulia A. Sorokina, Cand. Sci. (Biol.), Associate Professor of the Department of General and Clinical Pharmacology
10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950, Russia
O. V. Zanozina
Privolzhsky Research Medical University;
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko
Россия
Россия
Olga V. Zanozina, Dr. Sci. (Med.), Associate Professor, Professor of the Department of Therapy and General Medical Practice; Head of the Endocrinology Department
10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950, Russia
190, Rodionov St., Nizhny Novgorod, 603126, Russia
A. A. Mosinа
Privolzhsky Research Medical University
Россия
Россия
Anna A. Mosinа, Assistent of the Department of General and Clinical Pharmacology
10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950, Russia
I. D. Kapranova
Privolzhsky Research Medical University
Россия
Россия
Irina D. Kapranova, Student of the Faculty of Medicine
10/1, Minin and Pozharsky Square, Nizhny Novgorod, 603950, Russia
References
1. Klimontov VV, Tyan NV, Fazullina ON, Myakina NE, Lykov AP, Konenkov VI. Clinical and metabolic factors associated with chronic low-intensity inflammation in patients with type 2 diabetes mellitus. Diabetes Mellitus. 2016;19(4):295–202. (In Russ.) https://doi.org/10.14341/DM7928.
2. Mokasheva EN, Mokasheva EN. Leucocyte indices in therapeutic and surgical patients. Scientific Review. Medical Sciences. 2024;(3):24–29. (In Russ.) https://doi.org/10.17513/srms.1400.
3. Maamar M, Artime A, Pariente E, Fierro P, Ruiz Y, Gutiérrez S et al. PostCOVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin. 2022;38(6):901–909. https://doi.org/10.1080/03007995.2022.2042991.
4. Baluku JB, Nalwanga R, Kazibwe A, Olum R, Nuwagira E, Mugenyi N et al. Association between biomarkers of inflammation and dyslipidemia in drug resistant tuberculosis in Uganda. Lipids Health Dis. 2024;23(1):65. https://doi.org/10.1186/s12944-024-02063-7.
5. Chen HL, Wu C, Cao L, Wang R, Zhang TY, He Z. The association between the neutrophil-to-lymphocyte ratio and type 2 diabetes mellitus: a crosssectional study. BMC Endocr Disord. 2024;24(1):107. https://doi.org/10.1186/s12902-024-01637-x.
6. Zhang Y, Liu H. Correlation between insulin resistance and the rate of neutrophils-lymphocytes, monocytes-lymphocytes, plateletslymphocytes in type 2 diabetic patients. BMC Endocr Disord. 2024;24(1):42. https://doi.org/10.1186/s12902-024-01564-x.
7. Ghasempour Dabaghi G, Rabiee Rad M, Mortaheb M, Darouei B, AmaniBeni R, Mazaheri-Tehrani S et al. The Neutrophil-to-Lymphocyte Ratio Predicts Cardiovascular Outcomes in Patients With Diabetes: A Systematic Review and Meta-Analysis. Cardiol Rev. 2025;33(3):202–211. https://doi.org/10.1097/CRD.0000000000000820.
8. Chen G, Che L, Lai M, Wei T, Chen C, Zhu P, Ran J. Association of neutrophillymphocyte ratio with all-cause and cardiovascular mortality in US adults with diabetes and prediabetes: a prospective cohort study. BMC Endocr Disord. 2024;24(1):64. https://doi.org/10.1186/s12902-024-01592-7.
9. Hoes LLF, Riksen NP, Geleijnse JM, de Groot MCH, T van der Schouw Y, Visseren FLJ, Koopal C. Relationship of neutrophil-to-lymphocyte ratio, in addition to C-reactive protein, with cardiovascular events in patients with type 2 diabetes. Diabetes Res Clin Pract. 2024;213:111727. https://doi.org/10.1016/j.diabres.2024.111727.
10. Gong Y, Wang L, Li Q, Wang M, Luan R, Gao F, Hu L et al. Evaluating neutrophil-lymphocyte ratio, systemic immune-inflammation index, and systemic inflammation response index for diagnosing and predicting progression in diabetic retinopathy: a cross-sectional and longitudinal study. BMC Ophthalmol. 2025;25(1):398. https://doi.org/10.1186/s12886-025-04222-5.
11. Li J, Wang X, Jia W, Wang K, Wang W, Diao W et al. Association of the systemic immuno-inflammation index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with diabetic microvascular complications. Front Endocrinol. 2024;15:1367376. https://doi.org/10.3389/fendo.2024.1367376.
12. Yang X, Shi Y, Zhang H, Huang L, Zhang J, Min J, Chen L. Association between neutrophil-to-lymphocyte ratio and left ventricular diastolic dysfunction in patients with type 2 diabetes mellitus. Front Endocrinol. 2025;15:1499713. https://doi.org/10.3389/fendo.2024.1499713.
13. Joshi A, Bhambhani A, Barure R, Gonuguntla S, Sarathi V, Attia AM et al. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as markers of stable ischemic heart disease in diabetic patients: An observational study. Medicine. 2023;102(5):e32735. https://doi.org/10.1097/MD.0000000000032735.
14. Alfhili MA, Alsughayyir J, Basudan AM, Alsubki R, Alqahtani S, Awan ZA et al. Monocyte-Lymphocyte Ratio and Dysglycemia: A Retrospective, CrossSectional Study of the Saudi Population. Healthcare. 2022;10(11):2289. https://doi.org/10.3390/healthcare10112289.
15. Li H, Li Y, Guo W, Liu X, Wang Y, Zeng T, Kong W. Monocyte-lymphocyte ratio predicts cardiovascular diseases death in individuals with type 2 diabetes. J Diabetes Investig. 2025;16(1):137–145. https://doi.org/10.1111/jdi.14329.
16. Wu Y, Xiang HJ, Yuan M. Association of monocyte-lymphocyte ratio and myocardial infarction in the U.S. population with diabetes. Front Cardiovasc Med. 2024;11:1432838. https://doi.org/10.3389/fcvm.2024.1432838
17. Huang Q, Wu H, Wo M, Ma J, Fei X, Song Y. Monocyte-lymphocyte ratio is a valuable predictor for diabetic nephropathy in patients with type 2 diabetes. Medicine. 2020;99(19):e20190. https://doi.org/10.1097/MD.0000000000020190.
18. Kocak MZ, Aktas G, Duman TT, Atak BM, Kurtkulagi O, Tekce H et al. Monocyte lymphocyte ratio As a predictor of Diabetic Kidney Injury in type 2 Diabetes mellitus; The MADKID Study. J Diabetes Metab Disord. 2020;19(2):997–1002. https://doi.org/10.1007/s40200-020-00595-0.
19. Wang H, Guo Z, Xu Y. Association of monocyte-lymphocyte ratio and proliferative diabetic retinopathy in the U.S. population with type 2 diabetes. J Transl Med. 2022;20(1):219. https://doi.org/10.1186/s12967-022-03425-4.
20. Wang L, Gao J, Liu B, Fu Y, Yao Z, Guo S et al. The association between lymphocyte-to-monocyte ratio and all-cause mortality in obese hypertensive patients with diabetes and without diabetes: results from the cohort study of NHANES 2001-2018. Front Endocrinol. 2024;15:1387272. https://doi.org/10.3389/fendo.2024.1387272.
21. Li J, Zhao S, Zhang X, Fan M, Wan J, Lin R et al. Association of Systemic Inflammatory Response Index with the cardiometabolic multimorbidity among US adults: A population-based study. Brain Circ. 2025;11(1):39–47. https://doi.org/0.4103/bc.bc_32_24.
22. Patro S, Choudhary A, Sharma V, Mahajan A, Sahoo D, Pattnaik SS. Evaluating Platelet-to-Lymphocyte Ratio and Systemic ImmuneInflammation Index as Distinctive Biomarkers in Type 2 Diabetes Mellitus Patients With and Without Proteinuria: A Retrospective Study. Cureus. 2025;17(2):e79348. https://doi.org/10.7759/cureus.79348.
23. Gosav EM, Tanase DM, Ouatu A, Buliga-Finis ON, Popescu D, Dascalu CG et al. The Role of Neutrophil-to-Lymphocyte Ratio and Platelet-toLymphocyte Ratio in Predicting Atrial Fibrillation and Its Comorbidities. Life. 2025;15(6):960. https://doi.org/10.3390/life15060960.
24. Gao Y, Lu RX, Tang Y, Yang XY, Meng H, Zhao CL et al. Systemic immuneinflammation index, neutrophil-to-lymphocyte ratio, and platelet-tolymphocyte ratio in patients with type 2 diabetes at different stages of diabetic retinopathy. Int J Ophthalmol. 2024;17(5):877–882. https://doi.org/10.18240/ijo.2024.05.12.
25. Song Y, Lin Z, He J, Cui K, Song C, Zhang R et al. Association of platelet-tolymphocyte ratio levels with the risk of cardiac adverse events in people with type 2 diabetes undergoing percutaneous coronary intervention: A large-scale prospective cohort study. Diabetes Metab Syndr. 2024;18(3):102987. https://doi.org/10.1016/j.dsx.2024.102987.
26. Manaças LRA, Amorim RLO, Aguila A, Novo PC, Badin RC. Evaluation of hematological changes and immune response biomarkers as a prognostic factor in critical patients with COVID-19. PLoS ONE. 2024;19(2):e0297490. https://doi.org/10.1371/journal.pone.0297490.
27. Yılmaz A, Taşkın Ö, Demir U, Soylu VG. Predictive Role of Biomarkers in COVID-19 Mortality. Cureus. 2023;15(1):e34173. https://doi.org/10.7759/cureus.34173.
28. Ramos-Peñafiel CO, Santos-González B, Flores-López EN, Galván-Flores F, Hernández-Vázquez L, Santoyo-Sánchez A et al. Usefulness of the neutrophil-to-lymphocyte, monocyte-to-lymphocyte and lymphocyte-toplatelet ratios for the prognosis of COVID-19-associated complications. Gac Med Mex. 2020;156(5):405–411. https://doi.org/10.24875/GMM.M20000428.
29. Ghobadi H, Mohammadshahi J, Javaheri N, Fouladi N, Mirzazadeh Y, Aslani MR. Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts inhospital mortality in non-elderly and elderly COVID-19 patients. Front Med. 2022;9:916453. https://doi.org/10.3389/fmed.2022.916453.
30. Li J, Zhang Y, Wu R, Ma G, Sheng L, Feng Y et al. Evaluation of Inflammatory Markers in Patients with COVID-19 Combined with Type 2 Diabetes Mellitus. Risk Manag Healthc Policy. 2024;17:2535–2545. https://doi.org/10.2147/RMHP.S490281.
31. Dymicka-Piekarska V, Dorf J, Milewska A, Łukaszyk M, Kosidło JW, Kamińska J et al. Neutrophil/Lymphocyte Ratio (NLR) and Lymphocyte/Monocyte Ratio (LMR) – Risk of Death Inflammatory Biomarkers in Patients with COVID-19. J Inflamm Res. 2023;16:2209–2222. https://doi.org/10.2147/JIR.S409871.
32. Şener G, Bayrak T, Coşkun C, Bayrak A. Neutrophil Lymphocyte Ratio, Monocyte Lymphocyte Ratio, Platelet Lymphocyte Ratio in Covid-19 Patients. Clin Lab. 2022;68(3). https://doi.org/10.7754/Clin.Lab.2021.210639.
33. De Rop L, Bos DA, Stegeman I, Holtman G, Ochodo EA, Spijker R et al. Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2. Cochrane Database Syst Rev. 2024;8(8):CD015050. https://doi.org/10.1002/14651858.CD015050.pub2.
34. Ben S, Gao F, Xu Z, Zhang R, Zhang X, Wang N et al. The role of hematological parameters in asymptomatic and non-severe cases of Omicron variant infection. Virol J. 2024;21(1):143. https://doi.org/10.1186/s12985-024-02414-x.
35. Briciu V, Leucuta DC, Muntean M, Radulescu A, Cismaru C, Topan A et al. Differences in the inflammatory response and outcome among hospitalized patients during different waves of the COVID-19 pandemic. Front Immunol. 2025;16:1545181. https://doi.org/10.3389/fimmu.2025.1545181.
36. Fors M, Ballaz S, Ramírez H, Mora FX, Pulgar-Sánchez M, Chamorro K et al. Sex-Dependent Performance of the Neutrophil-to-Lymphocyte, Monocyteto-Lymphocyte, Platelet-to-Lymphocyte and Mean Platelet Volume-toPlatelet Ratios in Discriminating COVID-19 Severity. Front Cardiovasc Med. 2022;9:822556. https://doi.org/10.3389/fcvm.2022.822556.
37. Keskin M, Burcak Polat S, Ateş I, Izdeş S, Rahmet Güner H, Topaloğlu O et al. Are neutrophil-to-lymphocyte ratios and large unstained cells different in hospitalized COVID-19 PCR-positive patients with and without diabetes mellitus? Eur Rev Med Pharmacol Sci. 2022;26(16):5963–5970. https://doi.org/10.26355/eurrev_202208_29537.
38. Liu G, Zhang S, Hu H, Liu T, Huang J. The role of neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio in the prognosis of type 2 diabetics with COVID-19. Scott Med J. 2020;65(4):154–160. https://doi.org/10.1177/0036933020953516.
39. Danila AI, Cioca F, Gadde ST, Daruvuri SP, Timar R, Hogea E. Prognostic Utility of dNLR, ALRI, APRI, and SII in COVID-19 Patients with Diabetes: A Cross-Sectional Study. Diagnostics. 2024;14(15):1685. https://doi.org/10.3390/diagnostics14151685.
40. Jan MI, Anwar Khan R, Khan N, Iftikhar SM, Ali S, Khan MI et al. Modulation in serum and hematological parameters as a prognostic indicator of COVID-19 infection in hypertension, diabetes mellitus, and different cardiovascular diseases. Front Chem. 2024;12:1361082. https://doi.org/10.3389/fchem.2024.1361082.
41. Li J, Zhang Y, Wu R, Ma G, Sheng L, Feng Y et al. Evaluation of Inflammatory Markers in Patients with COVID-19 Combined with Type 2 Diabetes Mellitus. Risk Manag Healthc Policy. 2024;17:2535–2545. https://doi.org/10.2147/RMHP.S490281.
42. Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A Review of Persistent Post-COVID Syndrome (PPCS). Clin Rev Allergy Immunol. 2023;64(1):66–74. https://doi.org/10.1007/s12016-021-08848-3.
43. Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27(10):1507–1513. https://doi.org/10.1016/j.cmi.2021.05.033.
44. Salukhov VV, Arutyunov GP, Tarlovskaya EI, Batluk TI, Bashkinov RA, Samus IV et al. The impact of carbohydrate metabolism disorders on the early and long-term clinical outcomes of patients with COVID-19 according to the AKTIV and AKTIV 2 registries. Problemy Endokrinologii. 2023;69(1):36–49. (In Russ.) https://doi.org/10.14341/probl13175.
45. Sadovskiy IS, Kruglova OS, Savchenko AA, Sobko EA, Kasparov EV, Demko IV, Borisov AG. Complex inflammation indexes in patients with post-COVID syndrome. Russian Journal of Immunology. 2022;26(1):77–86. (In Russ.) https://doi.org/10.46235/1028-7221-1186-CII.
Review
For citations:
Sukhanov SA, Sorokina YA, Zanozina OV, Mosinа AA, Kapranova ID. Significance of certain leukocyte indices in patients with type 2 diabetes who have had novel coronavirus infection. Meditsinskiy sovet = Medical Council. 2025;(16):283–290. (In Russ.) https://doi.org/10.21518/ms2025-375
Views:
114
JATS XML
Email this article 